COMPANY

Rakuten Medical

HQ: San Diego, CA source · rakuten-med.com ↗

Rakuten Medical, Inc. is a biotechnology company developing and commercializing cell-targeting photoimmunotherapy based on its Alluminox platform. From company website Source · checked 2026-10-19

Sources for this description (1)

Rakuten Medical, Inc. is a biotechnology company developing and commercializing cell-targeting photoimmunotherapy based on its Alluminox platform.
- “Rakuten Medical, Inc. is a global biotechnology company developing and commercializing precision, cell-targeting photoimmunotherapy based on its proprietary Alluminox® platform, which, in pre-clinical studies, has been shown to induce rapid and selective cell killing and tumor necrosis.” https://rakuten-med.com/us/about/ (2026-10-19)

Modality: antibody

Keywords: oncology cancer Head and Neck Cancer Recurrent Head and Neck Squamous Cell Carcinoma Metastatic Head-and-neck Squamous-cell Carcinoma Locally Advanced Cutaneous Squamous Cell Carcinoma Metastatic Cutaneous Squamous Cell Carcinoma Squamous Cell Carcinoma of Head and Neck Cutaneous Squamous Cell Carcinoma Head and Neck Squamous Cell Carcinoma Recurrent Head and Neck Cancer ASP-1929 Photoimmunotherapy RM-1995

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

7Trials (company is sponsor)

Funding and NIH signals

SEC Form D raise Raised $8.97M (Form D filed Oct 6, 2026); +1 other Form D filing in the last 12 months. SEC Form D 0001595215-26-000002 (Oct 6, 2026)
Evidence (2 events)
- Oct 6, 2026 · SEC Form D 0001595215-26-000002
  Name of Issuer: Rakuten Medical, Inc.; CIK: 1595215; Address: San Diego, CA; Submission type: D; Filing date: 2026-10-06; Industry Group: Biotechnology; Date of First Sale: 2026-08-16; Types of Securities Offered: Option/warrant; Business combination transaction: false; Total Offering Amount: 8974943; Total Amount Sold: 8974943; Federal exemptions: 06b
- Apr 13, 2026 · SEC Form D 0001595215-26-000001
  Name of Issuer: Rakuten Medical, Inc.; CIK: 1595215; Address: San Diego, CA; Submission type: D; Filing date: 2026-04-13; Industry Group: Biotechnology; Date of First Sale: 2025-07-11; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 116672752; Total Amount Sold: 111522289; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Dec 24, 2024 Trial start Phase 3: A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metasta source ↗
Apr 19, 2022 Trial start Phase 2: ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases source ↗
Mar 24, 2022 Trial start Phase 1: RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC source ↗
Jan 21, 2022 Trial start Phase 2: ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer source ↗
Dec 21, 2020 Trial start Phase 1/Phase 2: An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors source ↗
May 9, 2019 Trial start Phase 3: ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy source ↗
2015-06 Trial start Phase 1/Phase 2: Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer source ↗

Upcoming milestones

2028-09 (ESTIMATED) · Phase 3 · A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases · NCT06699212

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 7

Record	Title	Phase	Status	Start	Primary completion
NCT06699212	A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases	Phase 3	Recruiting	Dec 24, 2024	2028-09 (estimated)
NCT04305795	An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors	Phase 1/Phase 2	Active, not recruiting	Dec 21, 2020	2026-06 (estimated)
NCT03769506	ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy	Phase 3	Active, not recruiting	May 9, 2019	2025-12 (estimated)
NCT05265013	ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases	Phase 2	Terminated	Apr 19, 2022	Nov 20, 2023 (actual)
NCT05182866	ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer	Phase 2	Unknown status (ClinicalTrials.gov)	Jan 21, 2022	Jul 11, 2024 (actual)
NCT05220748	RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC	Phase 1	Withdrawn	Mar 24, 2022	Jan 30, 2023 (actual)
NCT02422979	Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer	Phase 1/Phase 2	Completed	2015-06	Feb 25, 2019 (actual)